Sirtris Pharmaceuticals, Harvard Discover New Mechanism to Slow Aging
Sirtris Pharmaceuticals and Aging
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today publication of a study by Sirtris and Harvard University scientists in the journal Cell that reveals a new mechanism to slow aging. This study shows for the first time that activation of SIRT3 and SIRT4, members of the sirtuin family of enzymes, protects against cell damage. These important new findings further validate sirtuins as important targets for treating diseases of aging.
Sirtuins are a recently-discovered family of enzymes that promote the body's natural defense against disease. There are seven human sirtuins (SIRT1-7). Sirtuins are attractive drug targets because some have a specialized function in mitochondrial activity which may be therapeutically beneficial for metabolic and other diseases of aging. Sirtuin therapeutics offer the potential for a novel class of drugs that can treat diseases of aging in a new way. In 2006, Sirtris scientists published breakthrough data in the journals Nature and Cell, which demonstrated that SIRT1 activators appear to mimic calorie restriction and extend lifespan.
Christoph Westphal, M.D., Ph.D., Chief Executive Officer of Sirtris Pharmaceuticals added,